Sagar Lonial, MD from Winship Cancer Institute of Emory University discusses phase 2 trials of BCMA targeted therapy and finding safety, toxicity, and efficacy in a larger patient population at the 2017 American Society of Hematology.
Phase 2 Trials of BCMA Targeted Therapy – Find safety, toxicity, and efficacy in a larger patient population
